What makes this call so interesting is that the company just announced earlier this week that its management will present in a fireside chat at the 2012 Deutsche Bank Access BioFEST Conference on December 3, 2012 in Boston. With a focus on hepatitis B and C it seems as though investors are hoping that the company’s pipeline in Phase II studies will have significant upside since Idenix has estimated that more than 170 million people worldwide are chronically infected with HCV.
Shares are up a sharp 13% at $5.13 on the news and the volume is already closing in on 1 million shares after only about an hour of trading. Idenix has a $685 million market cap and shares have a 52-week range of $3.35 to $15.25. Another observation is that the consensus analyst target is already about $7.20 here with a range of $4.00 to $15.00 for the stock.
JON C. OGG
Travel Cards Are Getting Too Good To Ignore (sponsored)
Credit card companies are pulling out all the stops, with the issuers are offering insane travel rewards and perks.
We’re talking huge sign-up bonuses, points on every purchase, and benefits like lounge access, travel credits, and free hotel nights. For travelers, these rewards can add up to thousands of dollars in flights, upgrades, and luxury experiences every year.
It’s like getting paid to travel — and it’s available to qualified borrowers who know where to look.
We’ve rounded up some of the best travel credit cards on the market. Click here to see the list. Don’t miss these offers — they won’t be this good forever.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.